Information for "Any Phase Ib Study associated with Alpelisib or perhaps Buparlisib Coupled with Vemurafenib Plus Goserelin within Premenopausal Females using HRPositive HER2Negative Innovative Cancer of the breast"
From EECH Central
Basic information
| Display title | Any Phase Ib Study associated with Alpelisib or perhaps Buparlisib Coupled with Vemurafenib Plus Goserelin within Premenopausal Females using HRPositive HER2Negative Innovative Cancer of the breast |
| Default sort key | Any Phase Ib Study associated with Alpelisib or perhaps Buparlisib Coupled with Vemurafenib Plus Goserelin within Premenopausal Females using HRPositive HER2Negative Innovative Cancer of the breast |
| Page length (in bytes) | 4,176 |
| Page ID | 11895 |
| Page content language | English (en) |
| Page content model | wikitext |
| Indexing by robots | Allowed |
| Number of redirects to this page | 0 |
Page protection
| Edit | Allow all users (infinite) |
| Move | Allow all users (infinite) |
Edit history
| Page creator | Monthcopy4 (Talk | contribs) |
| Date of page creation | 08:33, 28 March 2023 |
| Latest editor | Monthcopy4 (Talk | contribs) |
| Date of latest edit | 08:33, 28 March 2023 |
| Total number of edits | 1 |
| Total number of distinct authors | 1 |
| Recent number of edits (within past 90 days) | 0 |
| Recent number of distinct authors | 0 |
